US Neurodegenerative Disease Market

ID: MRFR/LS/51020-HCR 200 Pages Vikita Thakur Last Updated: September 17, 2026
US Neurodegenerative Disease Market Research Report By Disease Type (Alzheimer's Disease, Parkinson's Disease, Multiple Sclerosis, Amyotrophic Lateral Sclerosis, Huntington's Disease), By Diagnosis Method (Neurological Examination, Imaging Techniques, Cerebrospinal Fluid Analysis, Electrophysiological Tests), By Treatment Type (Medication, Therapy, Rehabilitation, Surgical Interventions) and By Route of Administration (Oral, Injectable, Intravenous, Transdermal) -Forecast to 2035
US Neurodegenerative Disease Market
Market Size
Forecast Period2025 - 2035
CAGR (2025 - 2035)8.05%
2024 Market Size$ 14.5 Billion
2025 Market Size$ 15.67 Billion
2035 Market Size$ 34 Billion
Key Players
Biogen
Eli Lilly
Roche
Novartis
AstraZeneca
Merck & Co.
Trends
  • Rise of Personalized Medicine
  • Increased Investment in Research and Development
  • Expansion of Telehealth Services
Opportunities
  • Regulatory Support and Incentives
  • Increased Focus on Drug Development
  • Advancements in Diagnostic Technologies
Summary Table of Contents Segmentation Download PDF
  1. 1 SECTION I: EXECUTIVE SUMMARY AND KEY HIGHLIGHTS
    1. 1.1 EXECUTIVE SUMMARY
      1. 1.1.1 Market Overview
      2. 1.1.2 Key Findings
      3. 1.1.3 Market Segmentation
      4. 1.1.4 Competitive Landscape
      5. 1.1.5 Challenges and Opportunities
      6. 1.1.6 Future Outlook
  2. 2 SECTION II: SCOPING, METHODOLOGY AND MARKET STRUCTURE
    1. 2.1 MARKET INTRODUCTION
      1. 2.1.1 Definition
      2. 2.1.2 Scope of the study
        1. 2.1.2.1 Research Objective
        2. 2.1.2.2 Assumption
        3. 2.1.2.3 Limitations
    2. 2.2 RESEARCH METHODOLOGY
      1. 2.2.1 Overview
      2. 2.2.2 Data Mining
      3. 2.2.3 Secondary Research
      4. 2.2.4 Primary Research
        1. 2.2.4.1 Primary Interviews and Information Gathering Process
        2. 2.2.4.2 Breakdown of Primary Respondents
      5. 2.2.5 Forecasting Model
      6. 2.2.6 Market Size Estimation
        1. 2.2.6.1 Bottom-Up Approach
        2. 2.2.6.2 Top-Down Approach
      7. 2.2.7 Data Triangulation
      8. 2.2.8 Validation
  3. 3 SECTION III: QUALITATIVE ANALYSIS
    1. 3.1 MARKET DYNAMICS
      1. 3.1.1 Overview
      2. 3.1.2 Drivers
      3. 3.1.3 Restraints
      4. 3.1.4 Opportunities
    2. 3.2 MARKET FACTOR ANALYSIS
      1. 3.2.1 Value chain Analysis
      2. 3.2.2 Porter's Five Forces Analysis
        1. 3.2.2.1 Bargaining Power of Suppliers
        2. 3.2.2.2 Bargaining Power of Buyers
        3. 3.2.2.3 Threat of New Entrants
        4. 3.2.2.4 Threat of Substitutes
        5. 3.2.2.5 Intensity of Rivalry
      3. 3.2.3 COVID-19 Impact Analysis
        1. 3.2.3.1 Market Impact Analysis
        2. 3.2.3.2 Regional Impact
        3. 3.2.3.3 Opportunity and Threat Analysis
  4. 4 SECTION IV: QUANTITATIVE ANALYSIS
    1. 4.1 Construction, BY Disease Type (USD Billion)
      1. 4.1.1 Alzheimer's Disease
      2. 4.1.2 Parkinson's Disease
      3. 4.1.3 Multiple Sclerosis
      4. 4.1.4 Amyotrophic Lateral Sclerosis
      5. 4.1.5 Huntington's Disease
    2. 4.2 Construction, BY Diagnosis Method (USD Billion)
      1. 4.2.1 Neurological Examination
      2. 4.2.2 Imaging Techniques
      3. 4.2.3 Cerebrospinal Fluid Analysis
      4. 4.2.4 Electrophysiological Tests
    3. 4.3 Construction, BY Treatment Type (USD Billion)
      1. 4.3.1 Medication
      2. 4.3.2 Therapy
      3. 4.3.3 Rehabilitation
      4. 4.3.4 Surgical Interventions
    4. 4.4 Construction, BY Route of Administration (USD Billion)
      1. 4.4.1 Oral
      2. 4.4.2 Injectable
      3. 4.4.3 Intravenous
      4. 4.4.4 Transdermal
  5. 5 SECTION V: COMPETITIVE ANALYSIS
    1. 5.1 Competitive Landscape
      1. 5.1.1 Overview
      2. 5.1.2 Competitive Analysis
      3. 5.1.3 Market share Analysis
      4. 5.1.4 Major Growth Strategy in the Construction
      5. 5.1.5 Competitive Benchmarking
      6. 5.1.6 Leading Players in Terms of Number of Developments in the Construction
      7. 5.1.7 Key developments and growth strategies
        1. 5.1.7.1 New Product Launch/Service Deployment
        2. 5.1.7.2 Merger & Acquisitions
        3. 5.1.7.3 Joint Ventures
      8. 5.1.8 Major Players Financial Matrix
        1. 5.1.8.1 Sales and Operating Income
        2. 5.1.8.2 Major Players R&D Expenditure. 2023
    2. 5.2 Company Profiles
      1. 5.2.1 Biogen (US)
        1. 5.2.1.1 Financial Overview
        2. 5.2.1.2 Products Offered
        3. 5.2.1.3 Key Developments
        4. 5.2.1.4 SWOT Analysis
        5. 5.2.1.5 Key Strategies
      2. 5.2.2 Eli Lilly (US)
        1. 5.2.2.1 Financial Overview
        2. 5.2.2.2 Products Offered
        3. 5.2.2.3 Key Developments
        4. 5.2.2.4 SWOT Analysis
        5. 5.2.2.5 Key Strategies
      3. 5.2.3 Roche (CH)
        1. 5.2.3.1 Financial Overview
        2. 5.2.3.2 Products Offered
        3. 5.2.3.3 Key Developments
        4. 5.2.3.4 SWOT Analysis
        5. 5.2.3.5 Key Strategies
      4. 5.2.4 Novartis (CH)
        1. 5.2.4.1 Financial Overview
        2. 5.2.4.2 Products Offered
        3. 5.2.4.3 Key Developments
        4. 5.2.4.4 SWOT Analysis
        5. 5.2.4.5 Key Strategies
      5. 5.2.5 AstraZeneca (GB)
        1. 5.2.5.1 Financial Overview
        2. 5.2.5.2 Products Offered
        3. 5.2.5.3 Key Developments
        4. 5.2.5.4 SWOT Analysis
        5. 5.2.5.5 Key Strategies
      6. 5.2.6 Merck & Co. (US)
        1. 5.2.6.1 Financial Overview
        2. 5.2.6.2 Products Offered
        3. 5.2.6.3 Key Developments
        4. 5.2.6.4 SWOT Analysis
        5. 5.2.6.5 Key Strategies
      7. 5.2.7 Amgen (US)
        1. 5.2.7.1 Financial Overview
        2. 5.2.7.2 Products Offered
        3. 5.2.7.3 Key Developments
        4. 5.2.7.4 SWOT Analysis
        5. 5.2.7.5 Key Strategies
      8. 5.2.8 Sanofi (FR)
        1. 5.2.8.1 Financial Overview
        2. 5.2.8.2 Products Offered
        3. 5.2.8.3 Key Developments
        4. 5.2.8.4 SWOT Analysis
        5. 5.2.8.5 Key Strategies
      9. 5.2.9 AbbVie (US)
        1. 5.2.9.1 Financial Overview
        2. 5.2.9.2 Products Offered
        3. 5.2.9.3 Key Developments
        4. 5.2.9.4 SWOT Analysis
        5. 5.2.9.5 Key Strategies
    3. 5.3 Appendix
      1. 5.3.1 References
      2. 5.3.2 Related Reports
  6. 6 LIST OF FIGURES
    1. 6.1 MARKET SYNOPSIS
    2. 6.2 US MARKET ANALYSIS BY DISEASE TYPE
    3. 6.3 US MARKET ANALYSIS BY DIAGNOSIS METHOD
    4. 6.4 US MARKET ANALYSIS BY TREATMENT TYPE
    5. 6.5 US MARKET ANALYSIS BY ROUTE OF ADMINISTRATION
    6. 6.6 KEY BUYING CRITERIA OF CONSTRUCTION
    7. 6.7 RESEARCH PROCESS OF MRFR
    8. 6.8 DRO ANALYSIS OF CONSTRUCTION
    9. 6.9 DRIVERS IMPACT ANALYSIS: CONSTRUCTION
    10. 6.10 RESTRAINTS IMPACT ANALYSIS: CONSTRUCTION
    11. 6.11 SUPPLY / VALUE CHAIN: CONSTRUCTION
    12. 6.12 CONSTRUCTION, BY DISEASE TYPE, 2024 (% SHARE)
    13. 6.13 CONSTRUCTION, BY DISEASE TYPE, 2024 TO 2035 (USD Billion)
    14. 6.14 CONSTRUCTION, BY DIAGNOSIS METHOD, 2024 (% SHARE)
    15. 6.15 CONSTRUCTION, BY DIAGNOSIS METHOD, 2024 TO 2035 (USD Billion)
    16. 6.16 CONSTRUCTION, BY TREATMENT TYPE, 2024 (% SHARE)
    17. 6.17 CONSTRUCTION, BY TREATMENT TYPE, 2024 TO 2035 (USD Billion)
    18. 6.18 CONSTRUCTION, BY ROUTE OF ADMINISTRATION, 2024 (% SHARE)
    19. 6.19 CONSTRUCTION, BY ROUTE OF ADMINISTRATION, 2024 TO 2035 (USD Billion)
    20. 6.20 BENCHMARKING OF MAJOR COMPETITORS
  7. 7 LIST OF TABLES
    1. 7.1 LIST OF ASSUMPTIONS
  8. 7.1.1
    1. 7.2 US MARKET SIZE ESTIMATES; FORECAST
      1. 7.2.1 BY DISEASE TYPE, 2025-2035 (USD Billion)
      2. 7.2.2 BY DIAGNOSIS METHOD, 2025-2035 (USD Billion)
      3. 7.2.3 BY TREATMENT TYPE, 2025-2035 (USD Billion)
      4. 7.2.4 BY ROUTE OF ADMINISTRATION, 2025-2035 (USD Billion)
    2. 7.3 PRODUCT LAUNCH/PRODUCT DEVELOPMENT/APPROVAL
  9. 7.3.1
    1. 7.4 ACQUISITION/PARTNERSHIP
  10. 7.4.1

US Neurodegenerative Disease Market Segmentation

US Neurodegenerative Disease Market By Disease Type (USD Billion, 2025-2035)

  • Alzheimer's Disease
  • Parkinson's Disease
  • Multiple Sclerosis
  • Amyotrophic Lateral Sclerosis
  • Huntington's Disease

US Neurodegenerative Disease Market By Diagnosis Method (USD Billion, 2025-2035)

  • Neurological Examination
  • Imaging Techniques
  • Cerebrospinal Fluid Analysis
  • Electrophysiological Tests

US Neurodegenerative Disease Market By Treatment Type (USD Billion, 2025-2035)

  • Medication
  • Therapy
  • Rehabilitation
  • Surgical Interventions

US Neurodegenerative Disease Market By Route of Administration (USD Billion, 2025-2035)

  • Oral
  • Injectable
  • Intravenous
  • Transdermal

Related Reports

No regional reports available for this market.

No country-specific reports available for this market.

Customer Stories

Case Study Cover Image
Case Study

Aerospace & Defense

Future of Dismounted Soldier Systems Market Trends & Adoption Roadmap 2019–2035
Download PDF ×

We do not share your information with anyone. However, we may send you emails based on your report interest from time to time. You may contact us at any time to opt-out.